Details

Autor(en) / Beteiligte

• Hartung, Hans-Peter
• Kieseier, Bernd
• Goodin, Douglas S
• Arnason, Barry GW
• Comi, Giancarlo
• Cook, Stuart
• Filippi, Massimo
• Jeffery, Douglas R
• Kappos, Ludwig
• Bogumil, Timon
• Stemper, Brigitte
• Sandbrink, Rupert
• Nakada, Yukiko
• Nakajima, Haruhiko
• Schwenke, Susanne
• Lehr, Stephan
• Heubach, Jürgen
• Pohl, Christoph
• Reischl, Joachim

Titel

Variability in detection and quantification of interferon [beta]-1b-induced neutralizing antibodies

Ist Teil von

• Journal of neuroinflammation, 2012-06, Vol.9 (1), p.129-129

Ort / Verlag

London: BioMed Central Ltd

Erscheinungsjahr

2012

Link zum Volltext

Quelle

SpringerLink

Beschreibungen/Notizen

• Background Interferon-beta (IFNB) therapy for multiple sclerosis can lead to the induction of neutralizing antibodies (NAbs) against IFNB. Various methods are used for detection and quantification of NAbs. Methods Blood samples from 125 IFNB-1b-treated patients, which were tested NAb negative or NAb positive after conclusion of a clinical study, were retested three years after first being assessed in four different laboratories that offer routine NAb testing to practicing neurologists. The myxovirus protein A (MxA) induction assay, the cytopathic effect (CPE) assay (two laboratories), or the luciferase assay were used. Intra- and inter-laboratory agreement between assays with respect to NAb detection and NAb titer quantification were evaluated. Results High agreement for NAb detection (kappa coefficient, 0.86) and for titer levels was observed for the intra-laboratory comparison in the laboratory using the MxA induction assay performed three years ago and now. A similarly high agreement for NAb detection (kappa coefficient, 0.87) and for titer quantification was noted for the MxA assay of this laboratory with one of two laboratories using the CPE assay. All other inter-laboratory comparisons showed kappa values between 0.57 and 0.68 and remarkable differences in individual titer levels. Conclusions There are considerable differences in the detection and quantification of IFNB-induced NAbs among laboratories offering NAb testing for clinical practice using different assay methods. It is important that these differences are considered when interpreting NAb results for clinical decision-making and when developing general recommendations for potentially clinically meaningful NAb titer levels. Keywords: Multiple sclerosis, Clinical trials randomized controlled, IFNB-1b, Interferon beta, Neutralizing antibodies, Round robin